Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation

Virology Journal

Volumn 10, Issue , 2013, Pages

  Pleguezuelos, Olga ^a   Stoloff, Gregory A ^a   Caparrós Wanderley, Wilson ^a  

^a SEEK   (United Kingdom)

Author keywords

Antibodies; CD8+; Complement; HIV; Immunotherapy; Polypeptides; Vaccine

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CD8+ T LYMPHOCYTE; CELL DEATH; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; REVIEW; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84875687000     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-107     Document Type: Review

References (76)

1. Adverse effects of antiretroviral therapy for HIV infection. Montessori V, Press N, Harris M, Akagi L, Montaner JS, Can Med Ass J 2004 170 229 238
2. HIV treatment adherence, drug resistance, virologic failure: evolving concept s. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, Mills EJ, Gross R, Infect Disord Drug Targets 2011 11 167 174 10.2174/187152611795589663 21406048
3. Adverse effects of antiretroviral therapy. Carr A, Cooper DA, Lancet 2000 356 1423 1430 10.1016/S0140-6736(00)02854-3 11052597
4. Joint United Nations Programming on HIV/AIDS (UNAIDS), Global Report: UNAIDS Report on the global AIDS epidemic Geneva, Switzerland: WHO library Cataloguing-in-Publication Data ISBN 978-92-9173-592-1 Digital version 2012
5. Current progress in the development of a prophylactic vaccine for HIV-1. Gamble LJ, Matthews QL, Drug Des Devel Ther 2011 5 9 26
6. No acquisition: a new ambition for HIV vaccine development? Lakhashe SK, Silvestri G, Ruprecht RM, Curr Opin Virol 2011 1 246 253 10.1016/j.coviro.2011. 07.005 22081778
7. Searching for an effective, safe and universal anti-HIV vaccine. Lucchese G, Stufano A, Kanduc D, Self/Nonself 2011 2 49 54 10.4161/self.2.1.14762 21776335
8. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, Annappa S, Salles J-P, Loret EP, Retrovirology 2006 3 8 17 10.1186/1742-4690-3-8 16441880
9. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L, the NIAID HIV Vaccine Trials Network, Vaccine 2009 27 243 249 10.1016/j.vaccine.2008.10.051 18996425
10. A vaccine strategy against AIDS: An HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques. Vieillard V, Le Grand R, Dausset J, Debré P, PNAS 2008 105 2100 2104 10.1073/pnas.0711629105 18234855
11. Delayed progresión of murine AIDS in C57BL/6 mice pre-immunized with a highly antigenic 10-mer peptide encoded by the murine AIDS defective virus gag p12 gene. Mizuochi T, Horino A, Uchida T, Vaccine 1998 16 2026 2030 10.1016/S0264-410X(98)00082-6 9796060
12. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. Kelleher AD, Emery S, Cunningham P, Duncombe C, Carr A, Golding H, Forde S, Hudson J, Roggensack M, Forrest BD, Cooper DA, AIDS Res Hum Retroviruses 1997 13 29 32 10.1089/aid.1997.13.29 8989424
13. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Weber R, Bossart W, Cone R, Luethy R, Moelling K, Eur J Clin Microbiol Infect Dis 2001 20 800 803 10.1007/s100960100578 11783696
14. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ, HIV vaccine Trials Network of NIAID, J Infect Dis 2011 203 1165 1173 10.1093/infdis/jiq175 21451004
15. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM, J Virol 1998 72 1552 1576 9445059
16. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS, J Infect Dis 1996 173 340 348 10.1093/infdis/173.2.340 8568294
17. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MW, Step Study Protocol Team, Lancet 2008 372 1881 1893 10.1016/S0140-6736(08)61591-3 19012954
18. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumoo L, El-Habib R, Calvez V, Walker B, Katlama C, ORVACS Study Group, AIDS 2008 22 1313 1322 10.1097/QAD.0b013e3282fdce94 18580611
19. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. Rerks-Ngarn S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michel NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators, New Engl J Med 2009 361 2209 2220 10.1056/ NEJMoa0908492 19843557
20. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Altfeld M, Allen TM, Trends Immunol 2006 27 504 510 10.1016/j.it.2006. 09.007 16997629
21. The causes and consequences of HIV evolution. Rambaut A, Posada D, Crandall KA, Holmes EC, Nat Rev Genet 2004 5 52 61 10.1038/nrg1246 14708016
22. HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. Skar H, Borrego P, Wallstrom TC, Mild M, Marcelino JM, Barroso H, Taveira N, Leitner T, Albert J, J Virol 2010 84 7412 7415 10.1128/JVI.02548-09 20463072
23. HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses. Finnefrock AC, Liu X, Opalka DW, Shiver JW, Casimiro DR, Condra JH, AIDS Res Hum Retroviruses 2007 23 1283 1292 10.1089/aid.2007.0098 17961117
24. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ, Osmanov S, AIDS Res Hum Retroviruses 2000 16 1433 1443 10.1089/08892220050140982 11018863
25. HIV-1 Group M Conserved Elements Vaccine. Rolland M, Nickle DC, Mullins JI, PLoS Pathog 2007 3 157 10.1371/journal.ppat.0030157 18052528
26. Candidate vaccine sequences to represent intra and inter-clade HIV-1 variation. Yang OO, PLoS One 2009 4 7388 10.1371/journal.pone.0007388 19812689
27. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR, Nucleic Acid Res 2011 39 913 D919 10.1093/nar/gkq1128 21062830
28. New allele frequency database. Middleton D, Menchaca L, Rood H, Komerofsky R, Tissue Antigens 2003 61 403 407 http://www.allelefrequencies.net 10.1034/j.1399-0039.2003.00062.x 12753660
29. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Stoloff GA, Caparrós- Wanderley W, Eur J Immunol 2007 37 2441 2449 10.1002/eji.200737254 17668898
30. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W, Vaccine 2012 30 4655 4660 10.1016/j.vaccine.2012.04.089 22575166
31. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. De Groot AS, Jesdale B, Martin W, Saint Aubin C, Sbai H, Bosma A, Lieberman J, Skowron G, Mansourati F, Mayer KH, Vaccine 2003 21 4486 4504 10.1016/S0264-410X(03)00390-6 14505932
32. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Yewdell JW, Bennink JR, Annu Rev Immunol 1999 17 51 88 10.1146/annurev.immunol.17.1.51 10358753
33. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. Thorn M, Tang S, Therrien D, Kløverpris H, Vinner L, Kronborg G, Gerstoft J, Corbet S, Fomsgaard A, APMIS 2007 115 757 768 10.1111/j.1600-0463.2007.apm-595.x 17550385
34. Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Levitz L, Koita OA, Sangare K, Ardito MT, Boyle CM, Rozehnal J, Tounkara K, Dao SM, Koné Y, Koty Z, Buus S, Moise L, Martin WD, De Groot AS, Vaccine 2012 30 7547 7560 10.1016/j.vaccine.2012.10.042 23102976
35. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection. Cole GA, Hogg TL, Coppola MA, Woodland DL, J Immunol 1997 158 4301 4309 9126992
36. Protection against lethal viral infection by vaccination with non-immunodominant peptides. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, Vergnon I, Cordopatis P, Kosmatopoulos K, J Immunol 1996 157 3039 3045 8816413
37. HIV-1 Vif, APOBEC, and intrinsic immunity. Goila-Gaur R, Strebel K, Retrovirology 2008 5 51 10.1186/1742-4690-5-51 18577210
38. Nef enhances HIV-1 infectivity via association with the virus assembly complex. Qi M, Aiken C, Virology 2008 373 287 297 10.1016/j.virol.2007.12.001 18191978
39. The HIV-1 VPR protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line; possible implications for the pathogenesis of AIDS. Conti L, Rainaldi G, Matarrese P, Varano B, Rivabene R, Columba S, Sato A, Belardelli F, Malorni W, Gessani S, J Exp Med 1998 187 403 413 10.1084/jem.187.3.403 9449720
40. The VPR protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in non-dividing host cells. Heinzinger NK, Bukrinskyt MI, Haggerty SA, Ragland AM, Kewalramani V, Leet M-A, Gendelman HE, Ratner L, Stevenson M, Emerman M, Proc Nat Acad Sci USA 1994 91 7311 7315 10.1073/pnas.91.15.7311 8041786
41. Nuclear RNA export and packaging functions of HIV-1 REV revisited. Blissenbach M, Grewe B, Hoffmann B, Brandt S, Überla K, J Virol 2010 84 6598 6604 10.1128/JVI.02264-09 20427541
42. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Oberste MS, Gonda MA, Virus Genes 1992 6 95 102 10.1007/BF01703760 1312756
43. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. He Z, Zhang W, Chen G, Xu R, Yu XF, J Mol Biol 2008 381 1000 1011 10.1016/j.jmb.2008.06.061 18619467
44. Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. Mashishi T, Loubser S, Hide W, Hunt G, Morris L, Ramjee G, Abdool-Karim S, Williamson C, Gray CM, AIDS Res Hum Retroviruses 2001 17 1681 1687 10.1089/088922201753342103 11779357
45. A conserved HLA B13-restricted cytotoxic T lymphocyte epitope in Nef is a dominant epitope in HLA B13-positive HIV-1-infected patients. Harrer EG, Bergmann S, Eismann K, Rittmaier M, Goldwich A, Müller SM, Spriewald BM, Harrer T, AIDS 2005 19 734 735 10.1097/01.aids.0000166099.36638.56 15821402
46. Cross-clade conservation of HIV type 1 Nef immunodominant regions by CD8+ T cells of HIV type 1 CRF02-AG-infected Ivorian (West Africa). Inwoley A, Recordon-Pinson P, Dupuis M, Gaston J, Geněte M, Minga A, Letourneur F, Rouet F, Choppin J, Fleury H, Guillet JG, Andrieu M, ANRS 1220 PRIMO-CI Study group, AIDS Res Hum Retroviruses 2005 21 620 628 10.1089/aid.2005.21.620 16060833
47. Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation. Mahalingam S, Khan SA, Jabbar MA, Monken CE, Collman RG, Srinivasan A, Virology 1995 207 297 302 10.1006/viro.1995.1081 7871742
48. Mutants in a conserved region near the carboxy-terminus of HIV-1 Rev identify functionally important residues and exhibit a dominant negative phenotype. Venkatesh LK, Chinnadurai G, Virology 1990 178 327 330 10.1016/0042-6822(90)90414-M 2202148
49. CTL responses of HLA-A2.1-transgenic mice specific for Hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. Shirai M, Arichi T, Nichioka M, Nomura T, Ikeda K, Kawanishi K, Engelhard VH, Feinstone SM, Berzofsky JA, J Immunol 1995 154 2733 2742 7533182
50. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V, Expert Rev Vaccines 2002 1 111 118 10.1586/14760584.1.1.111 12908518
51. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Herrera S, Fernández OL, Vera O, Cárdenas W, Ramírez O, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M, AmJTrop Med Hyg 2011 84 12 20 10.4269/ajtmh.2011.09-0516
52. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, Andrieu M, Choppin J, Salmon D, Pialoux G, Guillet JG, AIDS Res Hum Retroviruses 2006 22 684 694 10.1089/aid.2006.22.684 16831093
53. Immunogenicity and safety of an HIV lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. Salmon-Cerón D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O, ANRS VAC18 trial group, AIDS 2010 24 2211 2223 10.1097/QAD.0b013e32833ce566 20625264
54. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. Le AX, Bernhard EJ, Holterman MJ, Strub S, Parham P, Lacy E, Engelhard VH, J Immunol 1989 142 1366 1371 2464645
55. Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Herberman RB, Nunn ME, Holden HT, Staal S, Djeu JY, Int J Cancer 1977 19 555 564 10.1002/ijc.2910190417 844921
56. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T, AIDS Res Hum Retroviruses 1992 8 553 558 10.1089/aid.1992.8.553 1381201
57. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Dugast AS, Tonelli A, Berger CT, Ackerman ME, Sciaranghella G, Liu Q, Sips M, Toth I, Piechocka-Trocha A, Ghebremichael M, Alter G, Virology 2011 415 160 167 10.1016/j.virol.2011.03.012 21565376
58. Activation of mouse complement by different classes of mouse antibody. Klaus GG, Pepys MB, Kitajima K, Askonas BA, Immunol 1979 38 687 695
59. Importance of immunoglobulin isotype in human antibody-dependent cell-mediated cytotoxicity directed by murine monoclonal antibodies. Kipps TJ, Parham P, Punt J, Herzenberg LA, J Exp Med 1985 161 1 17 10.1084/jem.161.1.1 3918141
60. Immunoglobulins and immunoglobulin genes. Potter M, The Mouse in Biomedical Research New York: Academic Press, Foster HL, Small JD, Fox JG, 1983 347 380
61. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO, FEMS Immunol Med Microbiol 2007 49 46 55 10.1111/j.1574-695X.2006. 00165.x 17094789
62. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Xiang Z, Ertl HC, Vaccine 1999 17 2003 2008 10.1016/S0264-410X(98) 00449-6 10217600
63. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Tomaras GD, Haynes BF, Curr Opin HIV AIDS 2009 4 373 379 10.1097/COH.0b013e32832f00c0 20048700
64. Antibodies to TAT and VPR in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Richardson MW, Mirchandani J, Duong J, Grimaldo S, Kocieda V, Hendel H, Khalili K, Zagury JF, Rappaport J, Biomed Pharmacother 2003 57 4 14 10.1016/S0753- 3322(02)00327-X 12642031
65. Detection of anti-REV antibodies in human immunodeficiency virus type-I patients using a recombinant 18KD REV protein. Tavernarakis N, Triantafyllaki A, Hatzakis A, Krambovitis E, Serodiagn Immunother Infect Dis 1993 5 117 121 10.1016/0888-0786(93)90052-2
66. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Jouvin-Marche E, Morgado MG, Leguern C, Voegtle D, Bonhomme F, Cazenave PA, Immunogenetics 1989 29 92 97 10.1007/BF00395856 2563358
67. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. Haas C, Ryffel B, Le Hir M, J Immunol 1997 158 5484 5491 9164971
68. The antibody response against HIV-1. Overbaugh J, Morris L, Cold Spring Harb Perspect Med 2012 2 007039 22315717
69. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC, Nature 2012 492 118 122 10.1038/nature11604 23103874
70. Non-neutralizing antibodies in prevention of HIV infection. Robinson HL, Expert Opin Biol Ther 2013 13 197 207 10.1517/14712598.2012.743527 23130709
71. Complement activation by human monoclonal antibodies to human immunodeficiency virus. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S, J Virol 1993 67 53 59 7677959
72. Antibody-dependent cellular cytotoxicity in HIV infections. Ahmad A, Menezes J, FASEB J 1996 10 258 266 8641559
73. Complement receptor type I (CR1, CD35) expression on peripheral T lymphocytes both CD4- and CD8- positive cells express CR1. Rødgaard A, Christensen LD, Thomsen BS, Wiik A, Bendixen G, Complement Inflamm 1991 8 303 309 1839374
74. Multiple sequence alignment with the Clustal series of programs. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD, Nucleic Acids Res 2003 31 3497 3500 10.1093/nar/gkg500 12824352
75. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Thompson JD, Higgins DG, Gibson TJ, Nucleic Acids Res 1994 22 4673 4680 10.1093/nar/22.22.4673 7984417
76. National Centre for Biotechnology Information (NCBI) Taxonomy database http://www.ncbi.nlm.nih.gov/protein/